New Retina Radio by Eyetube

Retina Today
  • 0,0 (0)
  • SCIENCES
  • TOUTES LES 2 SEMAINES
Podcast New Retina Radio by Eyetube

New Retina Radio is a place to hear stories about retina that are told nowhere else.

  1. -6 J

    New Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAO

    What is the relationship between retinal artery occlusion (RAO) and death, stroke, or myocardial infarction? Moderator Katherine Talcott, MD, is joined by Kyle Kovacs, MD, and Phoebe Mellen, MD, to explore the latest contribution to the literature on this topic. After the break, they discuss how best to manage patients who present to the clinic with an RAO, review academic centers' model for rapidly assessing patients with RAOs, and strategize how best to perform work-ups for patients who present to the retinal clinic with an RAO weeks after reporting reduced vision.

    16 min

  2. 5 SEPT.

    ASRS ’24: C1q Inhibition and Metformin for AMD

    Could inhibition of C1q effectively halt the progression of GA? Joel Pearlman, MD, PhD, sat down to discuss findings from the phase 2 ARCHER study, which evaluated ANX007 (Annexon) in patients with GA. He tells us what happened when patients were dosed with ANX007 for 1 year—and what occurred when patients stopped receiving treatment. And later, Dimitra Skondra, MD, fills us in on the latest research regarding potential interactions between metformin and AMD development in non-diabetic patients. Does the future of care include metformin as prophylaxis? Stick with us to find out.

    24 min

  3. 29 AOÛT

    New Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History of Anti-VEGF Therapy

    Does switching long-term wet AMD patients to faricimab (Vabysmo, Genentech/Roche) result in meaningful change to disease presentation? Join New Retina Radio Journal Club host Ben Young, MD, MS, and panelists Lediana Goduni, MD, and Josh Uhr, MD, as they break down a recent real-world study published in the literature. After the break, they review whether the study's findings could inform clinical decision-making, weigh the value of anatomic improvement that doesn't result in significant improvement in vision quality, and review their comfort with switching from legacy anti-VEGF agents to next-generation therapies.

    18 min

  4. 22 AOÛT

    ASRS ’24: PAVILION at 100 Weeks

    The Port Delivery System with Ranibizumab (PDS; Susvimo, Genentech) was shown to be effective for wet AMD treatment. What did the PAVILION study find when it came to treating diabetic retinopathy out to 100 weeks? Margaret Chang, MD, summarized the PAVILION study’s 2-year safety and efficacy findings regarding the PDS in patients with DR but no DME. Plus, Dr. Chang offers her opinions on what it will take for retina specialists to trust the PDS now that the next-generation model has been released. Hear what she has to say in this one-on-one interview.

    8 min

  5. 8 AOÛT

    ASRS ’24: ACP in Patients with Major EZ Attenuation, and GALE Microperimetry Findings

    Is avacincaptad pegol (Izervay, Astellas) effective in patients with major ellipsoid zone attenuation at baseline? Katherine Talcott, MD, stopped by our studio in Stockholm during ASRS with a top-line summary of her lecture at this year’s meeting. And Sunir Garg, MD, joined us for a conversation about the GALE study, which assessed 36 months of continuous dosing of pegcetacoplan (Syfovre, Apellis Pharmaceuticals). What did microperimetry findings reveal about long-term dosing with C3 inhibition? Join us in this episode to find out.

    16 min

  6. 19 JUIL.

    New Retina Radio Journal Club w/ VBS: Risk Factors for Switching from Bevacizumab to Aflibercept in Protocol AC

    Patients with DME in DRCR Retina Network Protocol AC were switched from bevacizumab to aflibercept if they met specific switch criteria. Where there any baseline factors that predicted a switch? Moderator Rebecca Soares, MD, sits down with panelists Matt Starr, MD, and Nikisha Kothari, MD, to review this study, ask whether the findings are clinically relevant, and explore other risk factors that may be worthy of further investigation.

    20 min

  7. 11 JUIL.

    From Trials to the Clinic: Using a Therapy With a Novel MOA to Treat Patients With DME

    One of the challenges associated with current anti-VEGF therapies for the management of DME is the need for frequent injections and the potential impact on adherence and vision outcomes. Join Dr. John Kitchens and Dr. Maria Berrocal as they share their experiences treating their DME patients using a therapy with a novel mechanism of action, and how those patient outcomes have influenced their extension decisions and treatment management approaches. This special episode of New Retina Radio, and its content, is supported by Genentech USA, Inc.

    30 min

  8. 27 JUIN

    New Retina Radio Journal Club w/ VBS: RVOs During the COVID Pandemic

    What did a review of the AAO IRIS Registry reveal about the rates of retinal vein occlusion (RVO) during the COVID-19 pandemic? Moderator Katherine Talcott, MD, sits down with Phoebe Mellen, MD, and Kyle Kovacs, MD, to review the study's conclusion that RVO rates did not increase during the pandemic, discuss challenges about talking to patients seeking causality for an ocular phenomenon, and review the relative strengths and drawbacks of relying on the IRIS Registry.

    15 min
Tout afficher (178)

À propos

New Retina Radio is a place to hear stories about retina that are told nowhere else.

Informations

  • Création
    Retina Today
  • Années d’activité
    2016 - 2024
  • Épisodes
    178
  • Classification
    Tous publics
  • Copyright
    © 2024 Bryn Mawr Communications LLC
  • Site web de l’émission
    New Retina Radio by Eyetube

Vous aimeriez peut‑être aussi

Pour écouter des épisodes au contenu explicite, connectez‑vous.

Recevez les dernières actualités sur cette émission

Connectez‑vous ou inscrivez‑vous pour suivre des émissions, enregistrer des épisodes et recevoir les dernières actualités.
Choisissez un pays ou une région

Afrique, Moyen‑Orient et Inde

Asie‑Pacifique

Europe

Amérique latine et Caraïbes

États‑Unis et Canada